Elicio Therapeutics, Inc.ELTX

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · elicio.com

Elicio Therapeutics is a clinical-stage biotechnology company advancing next-generation immunotherapies for the treatment of KRAS-driven cancers, including mKRAS-positive pancreatic and colorectal cancers. Its AMP technology aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance, with lead candidate ELI-002 7P targeting the most common KRAS mutations, which drive roughly 25% of all solid tumors.

Key ratios

ROA

-77.9%TTM

2025 -87.2%2024 -101.6%2023 -89.7%

ROE

-774.6%TTM

2024 -170157.4%2023 -347.0%

Recent news

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference 2026-08-31 · GlobeNewswire

Track ELTX in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer